Distinguished in Multiple Myeloma

Saskia K. Klein

Martini Ziekenhuis
Groningen, GR, NL 
Distinguished in Multiple Myeloma
Martini Ziekenhuis
Groningen, GR, NL 
OverviewLocationsClinical Research

Overview

Saskia Klein practices in Groningen, Netherlands. Ms. Klein is rated as a Distinguished expert by MediFind in the treatment of Multiple Myeloma. Her top areas of expertise are Multiple Myeloma, Myelodysplastic Syndrome (MDS), Leukemia, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

Her clinical research consists of co-authoring 57 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 19 articles and participated in 1 clinical trial in the study of Multiple Myeloma.

Gender
Female

Locations

Martini Ziekenhuis
Groningen, GR, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3

57 Total Publications

Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.
Structure-Activity Relationships of 3-Hydroxypropanamidines (HPAs) with Potent In Vivo Antimalarial Activity.
Journal: Journal of medicinal chemistry
Published: September 08, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Klein's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile